Interchange Capital Partners LLC Sells 1,094 Shares of Thermo Fisher Scientific Inc. $TMO

Interchange Capital Partners LLC lessened its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 94.2% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 67 shares of the medical research company's stock after selling 1,094 shares during the period. Interchange Capital Partners LLC's holdings in Thermo Fisher Scientific were worth $27,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in TMO. Nuveen LLC acquired a new position in shares of Thermo Fisher Scientific during the first quarter valued at $532,360,000. EdgePoint Investment Group Inc. acquired a new position in shares of Thermo Fisher Scientific during the first quarter valued at $172,139,000. Cohen Investment Advisors LLC lifted its stake in shares of Thermo Fisher Scientific by 6,655.5% during the first quarter. Cohen Investment Advisors LLC now owns 336,156 shares of the medical research company's stock valued at $167,271,000 after acquiring an additional 331,180 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Thermo Fisher Scientific by 13.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company's stock valued at $1,368,859,000 after acquiring an additional 329,974 shares during the period. Finally, Auto Owners Insurance Co lifted its stake in Thermo Fisher Scientific by 6,773.5% in the first quarter. Auto Owners Insurance Co now owns 288,000 shares of the medical research company's stock valued at $143,309,000 after buying an additional 283,810 shares during the period. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Trading Up 0.3%

NYSE TMO opened at $527.34 on Thursday. The firm has a market cap of $199.13 billion, a P/E ratio of 30.50, a P/E/G ratio of 2.85 and a beta of 0.77. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The stock's 50-day moving average is $492.55 and its 200-day moving average is $448.75. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $610.97.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same quarter last year, the firm earned $5.37 EPS. Thermo Fisher Scientific's revenue for the quarter was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have weighed in on TMO. Weiss Ratings reissued a "hold (c)" rating on shares of Thermo Fisher Scientific in a research note on Tuesday. Redburn Partners set a $580.00 target price on Thermo Fisher Scientific in a research note on Wednesday, October 8th. Wall Street Zen lowered Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research note on Sunday. Royal Bank Of Canada set a $561.00 target price on Thermo Fisher Scientific and gave the company an "outperform" rating in a research note on Tuesday, September 2nd. Finally, UBS Group increased their target price on Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a research note on Thursday, July 24th. Fifteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat, Thermo Fisher Scientific presently has a consensus rating of "Moderate Buy" and a consensus price target of $589.10.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the transaction, the executive vice president directly owned 22,367 shares in the company, valued at $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CAO Joseph R. Holmes sold 385 shares of the firm's stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the transaction, the chief accounting officer owned 2,319 shares of the company's stock, valued at approximately $1,142,408.97. This represents a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 30,066 shares of company stock worth $14,182,963 over the last ninety days. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.